Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study.
Alés-Martínez JE, Balmaña J, Sánchez-Rovira P, Salvador Bofill FJ, García Sáenz JÁ, Pimentel I, Morales S, Fernández-Abad M, Lahuerta Martínez A, Ferrer N, Zamora P, Bermejo B, Díaz-Redondo T, López-Ceballos MH, Galán M, Pérez-Escuredo J, Calabuig L, Sampayo M, Pérez-Garcia JM, Cortés J, Llombart-Cussac A.
Alés-Martínez JE, et al. Among authors: galan m.
Breast. 2024 Oct;77:103780. doi: 10.1016/j.breast.2024.103780. Epub 2024 Aug 2.
Breast. 2024.
PMID: 39116683
Free PMC article.
Clinical Trial.